Screener
Johnson & Johnson JNJ Accounts Receivable, Credit Loss Expense (Reversal)
Accounts Receivable, Credit Loss Expense (Reversal) at other companies
Other financials
Where this comes from
Reported directly by Johnson & Johnson in its filing.
Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.
The source filing: Johnson & Johnson’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000200406-26-000153
| Line item | Fiscal Six Months Ended / June 28,2026 | Fiscal Six Months Ended / June 29,2025 |
|---|---|---|
| Charges for acquired in-process research and development assets | 2 | 92 |
| Net loss/(gain) on sale of assets/businesses | (43) | (74) |
| Deferred tax provision | (320) | 2,997 |
| Credit losses and accounts receivable allowances | (12) | 3 |
| Changes in assets and liabilities, net of effects from acquisitions and divestitures: | ||
| Increase in accounts receivable | (1,947) | (2,283) |
| Increase in inventories | (1,002) | (656) |
| Decrease in accounts payable and accrued liabilities | (956) | (886) |
Item 1 — Financial statements
FAQ
- What is Johnson & Johnson's accounts receivable, credit loss expense (reversal)?
- Johnson & Johnson (JNJ) reported accounts receivable, credit loss expense (reversal) of -$4M in Q2 2026.
- How has Johnson & Johnson's accounts receivable, credit loss expense (reversal) changed year-over-year?
- Johnson & Johnson's accounts receivable, credit loss expense (reversal) decreased by 157.1% year-over-year, from $7M to -$4M.
- What is the long-term trend for Johnson & Johnson's accounts receivable, credit loss expense (reversal)?
- Over 2 years (2022 to 2024), Johnson & Johnson's accounts receivable, credit loss expense (reversal) has grown at a -19.6% compound annual growth rate (CAGR), from -$17M to $11M.
Ask your AI about Johnson & Johnson's accounts receivable, credit loss expense (reversal).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude